Literature DB >> 33203951

Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.

Kristina Maas-Bauer1, Chrissoula Kiote-Schmidt1, Hartmut Bertz1, Petya Apostolova1, Ralph Wäsch1, Gabriele Ihorst2, Jürgen Finke1, Robert Zeiser3.   

Abstract

Glucocorticoid-refractory (SR) chronic (c) graft-versus-host disease (GVHD) is a multisystem immunological disease and the leading cause of non-relapse mortality (NRM) in patients surviving longer than 2 years after allogeneic hematopoietic cell transplantation. Both ruxolitinib (RUX) and extracorporeal photopheresis (ECP) have shown activity for SR-cGVHD which motivated us to treat refractory cGHVD patients with the RUX-ECP combination. In this retrospective survey, 23 patients received RUX-ECP as salvage therapy for SR-cGVHD. The best response (CR or PR) at any time point during treatment was 74% (17/23) including 9% (2/23) CR and 65% (15/23) PR. The 24-months-survival was 75% (CI 56.0-94.1). Newly diagnosed cytopenia occurred in 22% (5/23) and CMV reactivation was observed in 26% (6/23) of the patients. Serum levels of soluble interleukin-2 receptor (sIL-2R) correlated with response. Our retrospective analysis shows that the RUX-ECP combination is safe and has activity in a fraction of patients with SR-cGVHD, which needs validation in a prospective trial.

Entities:  

Year:  2020        PMID： 33203951     DOI： 10.1038/s41409-020-01122-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  36 in total

1.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.

Authors:  Robert Zeiser; Nikolas von Bubnoff; Jason Butler; Mohamad Mohty; Dietger Niederwieser; Reuven Or; Jeff Szer; Eva M Wagner; Tsila Zuckerman; Bruyère Mahuzier; Judith Xu; Celine Wilke; Kunal K Gandhi; Gérard Socié
Journal:  N Engl J Med       Date:  2020-04-22       Impact factor: 91.245

2.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

3.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

4.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Brenda Kurland; Xiaoyu Chai; Navneet Majhail; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; David Jacobsohn; Jeanne Palmer; Sally Arai; Madan Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

5.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

6.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

7.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Authors:  Sally Arai; Madan Jagasia; Barry Storer; Xiaoyu Chai; Joseph Pidala; Corey Cutler; Mukta Arora; Daniel J Weisdorf; Mary E D Flowers; Paul J Martin; Jeanne Palmer; David Jacobsohn; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

8.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Authors:  Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

9.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

10.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113
View more
  7 in total

1.  Three US Food and Drug Administration-approved therapies for chronic GVHD.

Authors:  Robert Zeiser; Stephanie J Lee
Journal:  Blood       Date:  2022-03-17       Impact factor: 22.113

Review 2.  Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.

Authors:  Hildegard T Greinix; Francis Ayuk; Robert Zeiser
Journal:  Leukemia       Date:  2022-09-24       Impact factor: 12.883

3.  FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

Authors:  Robert Q Le; Xin Wang; Hongfei Zhang; Hongshan Li; Donna Przepiorka; Jonathon Vallejo; Ruby Leong; Lian Ma; Kirsten B Goldberg; Richard Pazdur; Marc R Theoret; Angelo De Claro
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

Review 4.  Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

5.  Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.

Authors:  Yingxin Zhao; Peng Chen; Liping Dou; Fei Li; Meng Li; Lingmin Xu; Jing Chen; Mingyu Jia; Sai Huang; Nan Wang; Songhua Luan; Jinling Yang; Nan Bai; Daihong Liu
Journal:  Drug Des Devel Ther       Date:  2022-03-25       Impact factor: 4.162

6.  Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Jae Sook Ahn; Hyeoung-Joon Kim; Sung Nam Lim; Jun Won Cheong; Sung-Yong Kim; Ho Sup Lee; Jong Ho Won; Ho-Young Yhim; Sang Kyun Sohn; Joon Ho Moon
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 7.  Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Hemasphere       Date:  2021-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.